News Tag: Other Corporate Information

Conference call on Interim Report

  • 05:00

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January – March 2021. The presentation will be held in English

Read more

Publication in The New England Journal of Medicine shows complications after liver transplantation significantly reduced with cold, oxygenated machine perfusion.

  • 15:30

An article published in the scientific journal The New England Journal of Medicine, shows that oxygenated perfusion of the donated liver before transplantation has a significant positive impact on the outcomes after transplantation. The study demonstrates two thirds lower rates of biliary complications, less hemodynamic compromise and that the incidence of early graft dysfunction is reduced by nearly half with oxygenated perfusion. The randomized trial, with livers donated after circulatory death, was performed in a large international consortium of liver transplant centers and included 156 patients. The Liver Assist device that was used for oxygenated perfusion in the trial, is CE-marked. XVIVO intends to submit an application for regulatory approval of the device to the FDA during 2021.

Read more

Publikation i The New England Journal of Medicine visar på signifikant minskning av komplikationer efter levertransplantation med syresatt, kall maskinperfusion

  • 15:30

En artikel publicerad i den vetenskapliga tidskriften The New England Journal of Medicine visar att syresatt maskinperfusion av den donerade levern har en betydande positiv inverkan på resultaten efter transplantation. Studien visar att frekvensen av gallvägskomplikationer reduceras med två tredjedelar, att cirkulatorisk instabilitet minskar samt att förekomsten av tidig leverdysfunktion nästan halveras. Den randomiserade studien utfördes i ett stort internationellt konsortium av levertransplantationscentra och inkluderade 156 patienter och organ donerade efter cirkulationsstillestånd. Maskinen som användes för syresatt perfusion i studien är CE-märkt och XVIVO avser att lämna in en ansökan om regulatoriskt godkännande till FDA under 2021.

Read more